What causes nosebleeds? The inside of your nose is lined with tiny, fragile blood vessels located close to the surface, and when they're injured, they bleed easily. Nosebleeds can be alarming, but ...
SAN DIEGO -- In a randomized trial, pomalidomide (Pomalyst) significantly reduced severe nosebleeds in patients with hereditary hemorrhagic telangiectasia (HHT), a condition with no approved therapy.
Each month, The Clinical Advisor makes one new clinical feature available ahead of print. Don’t forget to take the poll. The results will be published in the next month’s issue. Epistaxis, or acute ...
Experiencing a bloody nose can often feel like a minor, irritating event. For many, it’s nothing more than a sudden inconvenience that stops after a few minutes. But the truth is, frequent or severe ...
The American Academy of Otolaryngology-Head and Neck Surgery Foundation published the Clinical Practice Guideline: Nosebleed (Epistaxis) today in Otolaryngology-Head and Neck Surgery. A nosebleed is a ...
A placebo-controlled trial has shown that the oral AKT inhibitor engasertib could reduce the frequency and duration of ...
Nosebleeds are a common occurrence that many people experience at some point in their lives. While they often seem to happen without reason, several underlying health issues can cause them. From ...
ALEXANDRIA, VA - The American Academy of Otolaryngology-Head and Neck Surgery Foundation published the Clinical Practice Guideline: Nosebleed (Epistaxis) today in Otolaryngology-Head and Neck Surgery.
Nosebleeds occur when blood vessels in the nose burst and blood flows out. In response to this damage, the body forms a blood clot in the nose. It does this to reduce the blood leaking out and to ...
Bloody boogers form when blood mixes with mucus in the nose and the mucus dries. Various causes may include nose-picking or ruptured vessels. The nose lining is delicate and rich in blood vessels, and ...
MedPage Today on MSN
Investigational Oral Drug Shows Promise in Genetic Bleeding Disorder
Treatment with the investigational oral, allosteric, selective AKT inhibitor engasertib appeared to be safe in patients with hereditary hemorrhagic telangiectasia (HHT), and was associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results